Citigroup’s Medicines Co MDCO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-59,700
| Closed | -$5.07M | – | 7967 |
|
|
2019
Q4 | $5.07M | Sell |
59,700
-62,200
| -51% | -$4.15M | ﹤0.01% | 2019 |
|
|
2019
Q3 | $6.09M | Buy |
121,900
+57,100
| +88% | +$2.28M | ﹤0.01% | 1769 |
|
|
2019
Q2 | $2.36M | Sell |
64,800
-21,200
| -25% | -$692K | ﹤0.01% | 2671 |
|
|
2019
Q1 | $2.4M | Buy |
86,000
+33,500
| +64% | +$790K | ﹤0.01% | 2476 |
|
|
2018
Q4 | $1M | Buy |
52,500
+34,500
| +192% | +$803K | ﹤0.01% | 3395 |
|
|
2018
Q3 | $538K | Buy |
18,000
+13,300
| +283% | +$501K | ﹤0.01% | 4185 |
|
|
2018
Q2 | $172K | Sell |
4,700
-1,700
| -27% | -$55.2K | ﹤0.01% | 5209 |
|
|
2018
Q1 | $211K | Sell |
6,400
-3,800
| -37% | -$119K | ﹤0.01% | 4918 |
|
|
2017
Q4 | $279K | Sell |
10,200
-4,600
| -31% | -$142K | ﹤0.01% | 4728 |
|
|
2017
Q3 | $548K | Sell |
14,800
-2,500
| -14% | -$92.2K | ﹤0.01% | 4022 |
|
|
2017
Q2 | $658K | Sell |
17,300
-3,100
| -15% | -$138K | ﹤0.01% | 3738 |
|
|
2017
Q1 | $998K | Buy |
20,400
+6,400
| +46% | +$292K | ﹤0.01% | 3209 |
|
|
2016
Q4 | $475K | Sell |
14,000
-9,200
| -40% | -$326K | ﹤0.01% | 4424 |
|
|
2016
Q3 | $876K | Buy |
23,200
+15,700
| +209% | +$592K | ﹤0.01% | 3364 |
|
|
2016
Q2 | $252K | Sell |
7,500
-42,600
| -85% | -$1.5M | ﹤0.01% | 4286 |
|
|
2016
Q1 | $1.59M | Buy |
50,100
+16,300
| +48% | +$532K | ﹤0.01% | 2781 |
|
|
2015
Q4 | $1.26M | Buy |
33,800
+33,300
| +6,660% | +$1.26M | ﹤0.01% | 2881 |
|
|
2015
Q3 | $19K | Buy |
+500
| New | +$17.6K | ﹤0.01% | 6082 |
|
Other funds holding MDCO
Citigroup's MDCO Position: Q1 2020 in Review
Citigroup sold out of Medicines Co (MDCO) in Q1 2020, closing a stake of 2,541,983 shares — an estimated $216M sold.
Citigroup first reported a position in MDCO in Q2 2013 and held it in 27 quarters. The position peaked at $216M in Q4 2019. 1 fund tracked by Wall St. Rank holds MDCO as of Q1 2020.
- Citigroup reported no remaining Medicines Co position as of Q1 2020 after selling out during the quarter.
- Citigroup sold 2,541,983 Medicines Co shares in Q1 2020, an estimated $216M.
- Citigroup first reported a position in Medicines Co in Q2 2013 and held it in 27 quarters.
- Citigroup's Medicines Co position peaked at $216M in Q4 2019.
- 1 fund tracked by Wall St. Rank held Medicines Co as of Q1 2020.
Based on Citigroup's 13F filing for Q1 2020, filed 12 May 2020.